Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced today that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th.
Read full story
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) (PR Newswire via Yahoo! Finance)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. announced today that Savella , a selective se...
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of … (PR Newswire via Yahoo! Finance)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. announced today that they expect to ship Sav...
- Forest and Cypress Announce FDA Approval of Savella for the Management of Fibromyalgia
NEW YORK and SAN DIEGO, January 14, 2009, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.Re...
- Forest Laboratories and Cypress Bioscience Announce Study Shows…
- Forest Laboratories, Inc. And Cypress Bioscience, Inc. Announce Positive Results Of Phase III Study Of Milnacipran For … (Medical News Today)
Category: 
23 April 2009
Sorry, no comments yet.